Hofer Thomas U
Hoffmann-La Roche
31 Papers
164 Citations
Hofer Thomas U is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: T cell & Carcinoembryonic antigen. The author has an hindex of 10, co-authored 31 publications.
Chat about Author
Papers
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Marina Bacac,Tanja Fauti,Johannes Sam,Sara Colombetti,Tina Weinzierl,Djamila Ouaret,Walter F. Bodmer,Steffi Lehmann,Hofer Thomas U,Ralf Hosse,Ekkehard Moessner,Oliver Ast,Peter Bruenker,Sandra Grau-Richards,Teilo H Schaller,Annette Seidl,Christian Gerdes,Mario Perro,Nicolini Valeria G,Nathalie Steinhoff,Sherri Dudal,Sebastian Neumann,Thomas von Hirschheydt,Christiane Jaeger,Jose Saro,Vaios Karanikas,Christian Klein,Pablo Umana +27 more
TL;DR: CEA TCB is a novel generation TCB displaying potent antitumor activity; it is efficacious in poorly infiltrated tumors where it increases T-cell infiltration and generates a highly inflamed tumor microenvironment.
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein,Inja Waldhauer,Nicolini Valeria G,Anne Freimoser-Grundschober,Tapan K. Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn,Jörg Benz,Martine Stihle,Sabine Lang,Michaele Roemmele,Hofer Thomas U,Erwin van Puijenbroek,David Wittig,Samuel Moser,Oliver Ast,Peter Brünker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina De Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus A.M.S. van Dongen,Ekkehard Moessner,Pablo Umana +29 more
TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
245
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Christina Claus,Claudia Ferrara,Wei Xu,Johannes Sam,Sabine Lang,Franziska Uhlenbrock,Rosmarie Albrecht,Sylvia Herter,Ramona Schlenker,Tamara Hüsser,Sarah Diggelmann,John Challier,Ekkehard Mössner,Ralf Hosse,Hofer Thomas U,Peter Brünker,Catherine Joseph,Jörg Benz,Philippe Ringler,Henning Stahlberg,Matthias E. Lauer,Mario Perro,Stanford Chen,Christine Küttel,Preethi Latha Bhavani Mohan,Nicolini Valeria G,Martina Carola Birk,Amandine Ongaro,Christophe Prince,Reto Gianotti,Gregory O. Dugan,Christopher T. Whitlow,Kiran Kumar Solingapuram Sai,David L. Caudell,Armando G. Burgos-Rodriguez,J. Mark Cline,Michael Hettich,Maurizio Ceppi,Anna Maria Giusti,Flavio Crameri,Wouter H. P. Driessen,Peter N. Morcos,Anne Freimoser-Grundschober,Victor Levitsky,Maria Amann,Sandra Grau-Richards,Thomas von Hirschheydt,Stella Tournaviti,Michael Molhoj,Tanja Fauti,Viola Heinzelmann-Schwarz,Volker Teichgräber,Sara Colombetti,Marina Bacac,Alfred Zippelius,Christian Klein,Pablo Umana +56 more
TL;DR: FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.
230
Patent
Mutant interleukin-2 polypeptides
Oliver Ast,Peter Bruenker,Anne Freimoser-Grundschober,Sylvia Herter,Hofer Thomas U,Ralf Hosse,Christian Klein,Ekkehard Moessner,Nicolini Valeria G,Pablo Umana +9 more
- 07 Feb 2012
TL;DR: In this paper, the α-subunit α-interleukin-2 polypeptides were used as immunotherapeutic agents for the IL-2 receptor.
84
Capacity limits of asialoglycoprotein receptor-mediated liver targeting.
TL;DR: The kinetics of the ASGPR shows that saturation of the shuttle at therapeutic concentrations is possible; however, simulation allows the dosing schedule to be optimized, and the developed TMDD model can be used to support the development of therapies that use the AsGPR as a shuttle into hepatocytes.
59